 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Cypress Bioscience, Inc.
 |
Cypress Bioscience, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Cypress Bioscience licenses drug for fibromyalgia Aug 01 2001 01:31 PM PDT
Cypress Bioscience licenses drug for fibromyalgia Aug 01 2001 01:22 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Cypress Bioscience is no longer absorbed with PROSORBA. The biotech firm sold various rights to the PROSORBA column, which filters out the antibodies in the blood that attack healthy tissue and cause rheumatoid arthritis, to partner Fresenius to focus on developing therapies for other rheumatoid conditions. Its latest target is Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches, and fatigue -- and one that has no FDA-approved treatment. Cypress Bioscience is also targeting blood platelet disorders: Its Cyplex product candidate is an alternative to traditional platelet transfusions. Paramount Capital, an asset manager controlled by Dr. Lindsay Rosenwald, owns about 30% of the company.
COMPETITION |
 |
Baxter International Inc. (BAX)
Immunex Corporation (IMNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 3.00
1-Yr. Sales Growth: 57.9%
Employees: 6
Revenue per employee: $500,000.00
KEY PEOPLE |
 |
Jay D. Kranzler
CEO
Jay D. Kranzler
CFO
CONTACT INFO |
 |
4350 Executive Dr., Ste. 325
San Diego, CA 92121
US
Phone: 858-452-2323
Fax: 858-452-1222
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |